2014
DOI: 10.1186/s12879-014-0663-4
|View full text |Cite
|
Sign up to set email alerts
|

Persistent low carriage of serogroup A Neisseria meningitidistwo years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac

Abstract: BackgroundThe conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, is currently being introduced throughout the African meningitis belt. In repeated multicentre cross-sectional studies in Burkina Faso we demonstrated a significant effect of vaccination on NmA carriage for one year following mass vaccination in 2010. A new multicentre carriage study was performed in October-November 2012, two years after MenAfriVac mass vaccination.MethodsOropharyngeal samples were collected and analy… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

7
55
0

Year Published

2016
2016
2020
2020

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 57 publications
(64 citation statements)
references
References 45 publications
7
55
0
Order By: Relevance
“…The surveys conducted in the same sites a year after MenAfriVac R vaccination identified mostly NmX belonging to ST‐181 (5.33% of the samples) . Two years after MenAfriVac R vaccination, Nm W from ST‐11 cc dominated with a carriage prevalence of 6.85% .…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…The surveys conducted in the same sites a year after MenAfriVac R vaccination identified mostly NmX belonging to ST‐181 (5.33% of the samples) . Two years after MenAfriVac R vaccination, Nm W from ST‐11 cc dominated with a carriage prevalence of 6.85% .…”
Section: Resultsmentioning
confidence: 99%
“…The impact of group A meningococcal conjugate vaccine MenAfriVac R on pharyngeal carriage of the group A meningococcus in (a) Burkina Faso and (b) Chad . Figure a is modified from reference with permission.…”
Section: Resultsmentioning
confidence: 99%
“…In 2010, a low cost serogroup A polysaccharide-protein conjugate vaccine (MenAfriVac) was introduced [24]. The vaccine conferred protection against invasive disease [5, 6] as well as asymptomatic nasopharyngeal carriage of serogroup A strains [79], but failed to curtail disease or carriage by strains with serogroups C, X, or W, which also cause epidemics in the region [10–15]. Meningococcal A,C,Y and W conjugate vaccines, which are available in industrialized countries, can prevent epidemics caused by these strains.…”
Section: Introductionmentioning
confidence: 99%
“…16,17 In addition to persistent low carriage of meningococcal serogroup A, other serogroups like Y and X are causing meningococcal infections in sub-Saharan Africa. 7,[18][19][20] Therefore, designing novel meningococcal vaccine nanoparticles formulations that cover emerging and persistent meningococcal disease-causing serogroups with enhanced antigenicity have advantages over currently used conjugate vaccines. The novel nanotechnology-based formulations will provide suitable solution not just to low resource countries with endemic and heavy disease burden but also suitable for vaccinations required for the annual Hajj season.…”
Section: The Potential For Novel Meningococcal Vaccine Formulationsmentioning
confidence: 99%